From bench to bedside: translational advances, therapeutic targets, and delivery strategies in diabetic retinopathy.
Diabetic retinopathy (DR) is a leading cause of preventable blindness in adults of working age. Anti-vascular endothelial growth factor (anti-VEGF) therapy is the reference standard for diabetic macular edema (DME), yet in randomized cohorts, approximately 30-40% of DME eyes still show central macular thickening after...